Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF REGISTRATION APPLICATION FOR GERI MEDIUM (ONE PRODUCT OF GEMS SERIES EMBRYO CULTURE MEDIUM)

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on February 25, 2026, the Company obtained the Class III medical device registration certificate for its Geri Medium (one product of Gems series embryo culture medium) (registration certificate No.: Guo Xie Zhu Jin 20263180071) from the National Medical Products Administration of China (the "**NMPA**").

Before this approval, the Company's Geri Medium (one product of Gems series embryo culture medium) has already obtained European conformity (conformité européenne) ("**CE**"), Food and Drug Administration ("**FDA**"), and Therapeutic Goods Administration ("**TGA**") certifications. The core technology of this product originates from the in vitro fertilization center of Sydney. Combining the Geri Wet Time-Lapse incubator and AI embryo assessment system, the Geri Medium has officially entered clinical practice in China, solving the challenges of embryo culture for older patients with its dual core advantages of antioxidant formula and stable osmotic pressure environment.

The core technology of Geri Medium lies in developing a systematic solution addressing fertility challenges for older patients. Its "Triple Antioxidant Protection System" effectively addresses oxidative stress in aging embryos, and significantly streamlines laboratory procedures and ensures a stable culture environment when combined with the early addition of human serum albumin and extended stability. Internationally validated clinical studies demonstrate that this medium, when used with the Geri Wet Time-Lapse incubator and AI embryo assessment system, significantly improves high-quality blastocyst rates and clinical pregnancy rates, providing robust support for advanced-age fertility.

This approval marks a pivotal leap for the Company from technology introduction to localized production, filling the gap in domestic high-end assisted reproductive consumables market, and establishing the Company as the first enterprise in China holding four major internationally authoritative certifications, namely FDA, CE, TGA, and NMPA. Leveraging its core PGT technology and self-sufficient consumables supply, the Company now serves the vast majority of licensed PGT institutions nationwide and operates dozens of localized laboratories, forming a continuously evolving ecosystem barrier.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, February 26, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.